文献速递临床试验与 GCP流行病学与生物统计新药、器械与细胞基因治疗研发

双氢青蒿素-哌喹或磺胺多辛-乙胺嘧啶用于东部和南部非洲镰状细胞贫血儿童疟疾化学预防(CHEMCHA):多中心、两臂、双盲、随机、安慰剂对照优效性试验方案

Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-controlled superiority trial.
PubMed 文献 · Trials · 2023-04-05

CHEMCHA是一项在乌干达和马拉维开展的多中心、双盲、随机、安慰剂对照优效性试验,比较每周单日双氢青蒿素-哌喹(DP)与每月单日磺胺多辛-乙胺嘧啶(SP)在镰状细胞贫血(SCA)儿童中疟疾化学预防的效果。计划纳入548至824名SCA儿童,随访12至18个月,评估有效性、安全性、可接受性、 uptake和成本效果,并评估累积DP剂量的毒性和耐药性发展。招募于2021年4月30日开始,随访正在进行中。

要点

  • DP每周单日方案与SP每月单日方案在SCA儿童中比较疟疾化学预防效果。
  • 主要结局包括有效性、安全性、可接受性、 uptake和成本效果,随访12至18个月。
  • 将评估累积DP剂量毒性和耐药性发展。

核心结论

  • 研究结束时, findings将用于为区域卫生政策提供信息。
  • 当前方案为方案版本2.1,日期为2022年1月1日。

研究设计与样本

  • 多中心、两臂、双盲、随机、安慰剂对照优效性试验。
  • 在东部(乌干达)和南部(马拉维)非洲开展,按体重和研究中心分层随机化。
  • 参与者按1:1随机分配至DP或SP。
  • 计划纳入548至824名SCA儿童,随访12至18个月。

主要发现

  • 招募于2021年4月30日开始,随访正在进行中。
  • 试验在ClinicalTrials.gov注册,注册号NCT04844099,注册日期2021年4月8日。

关键数值与推荐

  • 干预组为每周单日DP方案,对照组为每月单日SP方案。
  • 随机化按体重和研究中心分层,分配比例1:1。
  • 样本量范围为548至824名SCA儿童。
  • 随访时长为12至18个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An estimated 300,000 babies are born with sickle cell anaemia (SCA) annually. Affected children have chronic ill health and suffer premature death. Febrile illnesses such as malaria commonly precipitate acute crises in children with SCA. Thus, chemoprophylaxis for malaria is an important preventive strategy, but current regimes are either sub-optimally effective (e.g. monthly sulphadoxine-pyrimethamine, SP) or difficult to adhere to (e.g. daily proguanil). We propose dihydroartemisinin-piperaquine (DP) as the agent with the most potential to be used across Africa. METHODS: This will be a randomised, double-blind, parallel-group superiority trial of weekly single-day courses of DP compared to monthly single-day courses of SP in children with SCA. The study will be conducted in eastern (Uganda) and southern (Malawi) Africa using randomisation stratified by body weight and study centre. Participants will be randomised using an allocation of 1:1 to DP or SP. We will investigate the efficacy, safety, acceptability and uptake and cost-effectiveness of malaria chemoprevention with weekly courses of DP vs monthly SP in 548 to 824 children with SCA followed up for 12-18 months. We will also assess toxicity from cumulative DP dosing and the development of resistance. Participant recruitment commenced on 30 April 2021; follow-up is ongoing. DISCUSSION: At the end of this study, findings will be used to inform regional health policy. This manuscript is prepared from protocol version 2.1 dated 1 January 2022. TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov, NCT04844099 . Registered on 08 April 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nkosi-Gondwe T, Robberstad B, Opoka R, et al. Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-controlled superiority trial. Trials. 2023. PMID: 37016392. doi:10.1186/s13063-023-07274-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。